Ladenburg Thalmann Financial Services’s Matinas BioPharma MTNB Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-500	Closed	-$16K	–	5431
2019 Q3	$16K	Hold	500	–	–	﹤0.01%	4161
2019 Q2	$21K	Hold	500	–	–	﹤0.01%	4026
2019 Q1	$27K	Hold	500	–	–	﹤0.01%	3816
2018 Q4	$15K	Buy	+500	New	+$19.6K	﹤0.01%	4039

Other funds holding MTNB

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Ladenburg Thalmann Financial Services's MTNB Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services sold out of Matinas BioPharma (MTNB) in Q4 2019, closing a stake of 500 shares — an estimated $16K sold.

Ladenburg Thalmann Financial Services first reported a position in MTNB in Q4 2018 and held it in 4 quarters. The position peaked at $27K in Q1 2019. 64 funds tracked by Wall St. Rank hold MTNB as of Q4 2019.

Ladenburg Thalmann Financial Services reported no remaining Matinas BioPharma position as of Q4 2019 after selling out during the quarter.
Ladenburg Thalmann Financial Services sold 500 Matinas BioPharma shares in Q4 2019, an estimated $16K.
Ladenburg Thalmann Financial Services first reported a position in Matinas BioPharma in Q4 2018 and held it in 4 quarters.
Ladenburg Thalmann Financial Services's Matinas BioPharma position peaked at $27K in Q1 2019.
64 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.